دورية أكاديمية
Effect of PET-CT on disease recurrence and management in patients with potentially resectable colorectal cancer liver metastases. Long-term results of a randomized controlled trial.
| العنوان: | Effect of PET-CT on disease recurrence and management in patients with potentially resectable colorectal cancer liver metastases. Long-term results of a randomized controlled trial. |
|---|---|
| المؤلفون: | Serrano PE; Department of Surgery, McMaster University, Hamilton, Ontario.; Ontario Clinical Oncology Group, McMaster University, Hamilton, Ontario., Gu CS; Ontario Clinical Oncology Group, McMaster University, Hamilton, Ontario.; Department of Oncology, McMaster University, Hamilton, Ontario., Moulton CA; University Health Network, Toronto, Ontario., Husien M; Grand River Regional Cancer Centre, Kitchener, Ontario., Jalink D; Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario., Martel G; The Ottawa Hospital, Ottawa, Ontario., Tsang ME; St. Joseph's Health Centre, Toronto, Ontario., Hallet J; Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario., McAlister V; London Health Sciences Centre, London, Ontario., Gallinger S; University Health Network, Toronto, Ontario., Levine M; Ontario Clinical Oncology Group, McMaster University, Hamilton, Ontario.; Department of Oncology, McMaster University, Hamilton, Ontario. |
| المصدر: | Journal of surgical oncology [J Surg Oncol] 2020 May; Vol. 121 (6), pp. 1001-1006. Date of Electronic Publication: 2020 Feb 07. |
| نوع المنشور: | Journal Article; Randomized Controlled Trial |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0222643 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-9098 (Electronic) Linking ISSN: 00224790 NLM ISO Abbreviation: J Surg Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2005-> : Hoboken, NJ : Wiley-Liss Original Publication: New York, Plenum. |
| مواضيع طبية MeSH: | Colorectal Neoplasms/*diagnostic imaging , Colorectal Neoplasms/*surgery , Liver Neoplasms/*diagnostic imaging , Liver Neoplasms/*surgery , Neoplasm Recurrence, Local/*pathology, Colorectal Neoplasms/pathology ; Disease-Free Survival ; Humans ; Liver Neoplasms/pathology ; Liver Neoplasms/secondary ; Neoplasm Recurrence, Local/diagnostic imaging ; Neoplasm Staging ; Positron Emission Tomography Computed Tomography ; Survival Rate |
| مستخلص: | Background: Preoperative evaluation of resectable colorectal cancer liver metastases with positron emission tomography (PET) combined with computed tomography (PET-CT) is used extensively. The PETCAM trial evaluated the effect of PET-CT (intervention) vs no PET-CT (control) on surgical management. PET-CT resulted in 8% change in surgical management, therefore, we aimed to compare long-term outcomes (disease-free [DFS], overall survival [OS]). Methods: Trial recruitment (2005-2010) had prospective follow-up until 2013. Events from 2013 to 2017 were collected retrospectively. Survival was described by the Kaplan-Meier method and compared with log-rank test. Oncologic risk factors were calculated using Cox proportional hazard models. Results: Among 404 patients randomized, there were no differences in DFS (hazard ratio [HR] = 1.13; 95% confidence interval [CI], 0.89 to 1.43) or OS (HR, 1.02; 95% CI, 0.78-1.32) between groups. For all patients randomized, median DFS (PET-CT vs no PET-CT) was 16 months (95% CI, 13-18) and 15 months (95% CI, 11-22), P = .33. For patients who underwent liver resection (n = 368), DFS (17 vs 16 months, P = .51) and OS (58 months vs 52 months, P = .90) were similar between groups, respectively. Risk factors for DFS and OS were age, tumor size, node-positive disease, extrahepatic metastases and disease-free duration. Conclusion: Preoperative PET-CT changes surgical management in a small percentage of cases, without effect on recurrence rates or long-term survival. (© 2020 Wiley Periodicals, Inc.) |
| References: | Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P. Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg. 2003;90(5):567-574. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004;240(6):1027-1034. discussion 1035-1026. Cipe G, Ergul N, Hasbahceci M, et al. Routine use of positron-emission tomography/computed tomography for staging of primary colorectal cancer: does it affect clinical management? World J Surg Oncol. 2013;11:49. McLeish AR, Lee ST, Byrne AJ, Scott AM. Impact of (1)(8)F-FDG-PET in decision making for liver metastectomy of colorectal cancer. ANZ J Surg. 2012;82(1-2):30-35. Amin A, Reddy A, Wilson R, Jha M, Miranda S, Amin J. Unnecessary surgery can be avoided by judicious use of PET/CT scanning in colorectal cancer patients. J Gastrointest Cancer. 2012;43(4):594-598. Engledow AH, Skipworth JR, Pakzad F, Imber C, Ell PJ, Groves AM. The role of 18FDG PET/CT in the management of colorectal liver metastases. Hepato Pancreato Biliary. 2012;14(1):20-25. Ruers TJM, Wiering B, van der Sijp JRM, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med. 2009;50(7):1036-1041. Daza JF, Solis NM, Parpia S, et al. A meta-analysis exploring the role of PET and PET-CT in the management of potentially resectable colorectal cancer liver metastases. Eur J Surg Oncol. 2019;45(8):1341-1348. Moulton CA, Gu CS, Law CH, et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA. 2014;311(18):1863-1869. Serrano PE, Gafni A, Gu CS, et al. Positron emission tomography-computed tomography (PET-CT) versus no PET-CT in the management of potentially resectable colorectal cancer liver metastases: cost implications of a randomized controlled trial. J Oncol Pract. 2016;12(7):e765-e774. Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1261-1268. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575-4580. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208-1215. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the surveillance, epidemiology, and end results (SEER) program. Oncologist. 2003;8(6):541-552. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759-766. Neal CP, Nana GR, Jones M, et al. Repeat hepatectomy is independently associated with favorable long-term outcome in patients with colorectal liver metastases. Cancer Med. 2017;6(2):331-338. Petrowsky H, Gonen M, Jarnagin W, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg. 2002;235(6):863-871. Acciuffi S, Meyer F, Bauschke A, et al. Analysis of prognostic factors after resection of solitary liver metastasis in colorectal cancer: a 22-year bicentre study. J Cancer Res Clin Oncol. 2018;144(3):593-599. Bellier J, De Wolf J, Hebbar M, et al. Repeated resections of hepatic and pulmonary metastases from colorectal cancer provide long-term survival. World J Surg. 2018;42(4):1171-1179. Lintoiu-Ursut B, Tulin A, Constantinoiu S. Recurrence after hepatic resection in colorectal cancer liver metastasis -Review article. J Med Life. 2015;8:12-14. Spec Issue. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309-318. discussion 318-321. Konopke R, Kersting S, Distler M, et al. Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int. 2009;29(1):89-102. Muto T, Nagawa H, Nagashima I, et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobil Pancreat Surg. 2004;11(2):79-83. Nordlinger B, Van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20(6):985-992. Hallet J, Sa Cunha A, Adam R, et al. Factors influencing recurrence following initial hepatectomy for colorectal liver metastases. Br J Surg. 2016;103(10):1366-1376. |
| معلومات مُعتمدة: | grant-in-aid Ontario Ministry of Health & Long-term Care |
| فهرسة مساهمة: | Keywords: Overall survival; PET-CT; colorectal cancer liver metastases; disease-free survival |
| تواريخ الأحداث: | Date Created: 20200209 Date Completed: 20200424 Latest Revision: 20200424 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1002/jso.25864 |
| PMID: | 32034769 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1096-9098 |
|---|---|
| DOI: | 10.1002/jso.25864 |